Company overview
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing ENTA with another company.
| Daily close (USD) | $12.1 |
| Market capitalization (USD) | $352,417,364.2 |
| Price / earnings (TTM) | Not reported |
| Price / book | 3.49 |
No matching rows. Clear the filter to see all records.
Read ENTA's valuation metrics
Company size
Enanta Pharmaceuticals, Inc's recorded market capitalization is $352,417,364.2. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
ENTA's recorded price-to-book ratio is 3.49. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Enanta Pharmaceuticals, Inc with Aurora
Use the snapshot above to ask a specific question about ENTA. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow ENTA's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.